{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:50:44Z","timestamp":1786121444086,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011541","name":"National Cancer Institute Division of Cancer Epidemiology and Genetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clml.2026.06.001","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T23:50:45Z","timestamp":1781049045000},"page":"e1035-e1042.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Potential Benefits and Harms of Screening Strategies for Monoclonal Gammopathy of Undetermined Significance in the US: A Simulation Study"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7853-7240","authenticated-orcid":false,"given":"Ishfaq","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2169-4174","authenticated-orcid":false,"given":"Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9038-077X","authenticated-orcid":false,"given":"Natalia","family":"Neparidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0014-9679","authenticated-orcid":false,"given":"Jane","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3294-5784","authenticated-orcid":false,"given":"Shi-Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2026.06.001_bib0001","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2026.06.001_bib0002","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2026.06.001_bib0003","unstructured":"National Cancer Institute. Cancer incidence: Surveillance, Epidemiology, and End results (SEER) registries research data. https:\/\/seer.cancer.gov\/data. Assessed April 27, 2023."},{"key":"10.1016\/j.clml.2026.06.001_bib0004","unstructured":"National Cancer Institute. Cancer Stat Facts: Myeloma. Surveillance, Epidemiology, and End Results Program. Bethesda (MD): National Cancer Institute. Available from: [SEER Myeloma Stat Facts]. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"10.1016\/j.clml.2026.06.001_bib0005","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.clml.2014.05.004","article-title":"Asymptomatic monoclonal gammopathies","volume":"14","author":"Bories","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.06.001_bib0006","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: IMWG consensus perspectives for progression and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.06.001_bib0007","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1001\/jama.2015.12783","article-title":"Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society","volume":"314","author":"Oeffinger","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2026.06.001_bib0008","doi-asserted-by":"crossref","first-page":"279","DOI":"10.7326\/M15-2886","article-title":"Screening for breast cancer: U.S. preventive services task force recommendation statement","volume":"164","author":"Siu","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2026.06.001_bib0009","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1056\/NEJMcp1512286","article-title":"Screening for colorectal neoplasia","volume":"376","author":"Inadomi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.06.001_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.17.00131","article-title":"Computational model of progression to multiple myeloma identifies optimum screening strategies","volume":"2","author":"Altrock","year":"2018","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.clml.2026.06.001_bib0011","unstructured":"PROMISE Study Investigators. Predicting progression of developing myeloma in a high-risk screened population (PROMISE). Clin Trial Descript. Available at: https:\/\/www.enroll.promisestudy.org\/"},{"key":"10.1016\/j.clml.2026.06.001_bib0012","first-page":"251","article-title":"The Iceland Screens, treats, or Prevents Multiple Myeloma (iStopMM) study: a population-based screening study for monoclonal gammopathy of undetermined significance and a randomized controlled trial of follow-up strategies","volume":"135","author":"Sigurdardottir","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.06.001_bib0013","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1158\/1940-6207.CAPR-13-0224","article-title":"Regular aspirin use and risk of multiple myeloma: a prospective analysis in the health professionals follow-up study and nurses' health study","volume":"7","author":"Birmann","year":"2014","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.clml.2026.06.001_bib0014","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S2352-3026(14)00037-4","article-title":"Metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma","volume":"2","author":"Chang","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2026.06.001_bib0015","first-page":"343","article-title":"Monoclonal gammopathy of undetermined significance: to screen or not to screen","volume":"10","author":"Ong","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.clml.2026.06.001_bib0016","unstructured":"National Cancer Institute, CISNET Multiple Myeloma Working Group. Multiple myeloma model profiles and registry. https:\/\/cisnet.cancer.gov\/multiplemyeloma. Assessed October 1, 2025."},{"key":"10.1016\/j.clml.2026.06.001_bib0017","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.clml.2014.09.004","article-title":"Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis","volume":"15","author":"Go","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.06.001_bib0018","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/s41375-019-0419-7","article-title":"Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma","volume":"33","author":"Goyal","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.06.001_bib0019","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2015.23","article-title":"The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma","author":"Sigurdardottir","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2026.06.001_bib0020","first-page":"1172","article-title":"The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in monoclonal gammopathy of undetermined significance","volume":"86","author":"Gregersen","year":"2001","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.06.001_bib0021","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s12185-018-2555-7","article-title":"Characteristics and prognosis of non-immunoglobulin M monoclonal gammopathy of undetermined significance: a retrospective study","volume":"109","author":"Kuwabara","year":"2019","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2026.06.001_bib0022","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S2352-3026(22)00386-6","article-title":"Personalized progression prediction in monoclonal gammopathy of undetermined significance or smoldering multiple myeloma (PANGEA): a retrospective multicohort study","volume":"10","author":"Cowan","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2026.06.001_bib0023","unstructured":"Centers for Disease Control and Prevention, National Center for Health Statistics. National Health and Nutrition Examination Survey: response rates and population totals. https:\/\/wwwn.cdc.gov\/nchs\/nhanes\/ResponseRates.aspx. Accessed June 25, 2026."},{"key":"10.1016\/j.clml.2026.06.001_bib0024","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2014.34","article-title":"Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutrition Examination Survey","volume":"28","author":"Landgren","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.06.001_bib0025","unstructured":"National Cancer Institute. SEER Cancer Statistics Review, 1975\u20132003. Prevalence of invasive multiple myeloma on January 1, 2003. https:\/\/seer.cancer.gov\/archive\/csr\/1975_2003\/. Assessed April 27, 2023."},{"key":"10.1016\/j.clml.2026.06.001_bib0026","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.1038\/s41467-023-41223-8","article-title":"Disentangling age, gender, and racial or ethnic disparities in multiple myeloma burden: a modeling study","volume":"14","author":"Huber","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2026.06.001_bib0027","unstructured":"Centers for disease control and prevention. United States life tables, 2003-2020. https:\/\/www.cdc.gov\/nchs\/products\/life_tables.htm. Accessed April 27, 2023."},{"key":"10.1016\/j.clml.2026.06.001_bib0028","article-title":"Quantifying the contribution of modifiable risk factors for progression of MGUS to multiple myeloma","author":"Wang","year":"2025","journal-title":"medRxiv"},{"key":"10.1016\/j.clml.2026.06.001_bib0029","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2023.2278","article-title":"Mortality in U.S. populations with monoclonal gammopathy of undetermined significance","author":"Ji","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2026.06.001_bib0030","unstructured":"Surveillance, Epidemiology, and end results (SEER) program SEER*stat database: incidence - SEER 9 regs research data, Nov 2023 sub (2000-2021) - linked to county attributes - time dependent (1990-2022) income\/rurality, 1969-2022. www.seer.cancer.gov. Accessed June 25, 2026."},{"issue":"9","key":"10.1016\/j.clml.2026.06.001_bib0031","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/jnci\/djq099","article-title":"Overdiagnosis in cancer","volume":"102","author":"Welch","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.clml.2026.06.001_bib0032","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.7326\/M23-0133","article-title":"Estimating breast cancer overdiagnosis after screening mammography among older women in the United States","volume":"176","author":"Richman","year":"2023","journal-title":"Ann Int Med"},{"key":"10.1016\/j.clml.2026.06.001_bib0033","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/pon.904","article-title":"The psychological impact of mammographic screening: a systematic review","volume":"14","author":"Brett","year":"2005","journal-title":"Psychooncology"},{"key":"10.1016\/j.clml.2026.06.001_bib0034","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0090-4295(02)01552-2","article-title":"Impact of prostate cancer screening on health-related quality of life in at-risk families","volume":"59","author":"Cormier","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.clml.2026.06.001_bib0035","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-021-00480-w","article-title":"Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies","volume":"11","author":"Rognvaldsson","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.06.001_bib0036","doi-asserted-by":"crossref","first-page":"e1145","DOI":"10.1016\/j.clml.2025.09.016","article-title":"The unmet psychological needs of people living with multiple myeloma and smoldering myeloma","volume":"25","author":"Tuckey","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.06.001_bib0037","doi-asserted-by":"crossref","first-page":"54","DOI":"10.46989\/001c.123608","article-title":"Psychological impact in individuals with monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"6","author":"Patel","year":"2024","journal-title":"Clin Hematol Int"},{"issue":"1","key":"10.1016\/j.clml.2026.06.001_bib0038","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.125.042187","article-title":"Association between monoclonal gammopathy of undetermined significance and cardiovascular disease risk: a Veterans Health Administration study","volume":"15","author":"Michaud","year":"2026","journal-title":"J Am Heart Assoc"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T05:02:11Z","timestamp":1786078931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026001758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2152265026001758"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.06.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential Benefits and Harms of Screening Strategies for Monoclonal Gammopathy of Undetermined Significance in the US: A Simulation Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}